AstraZeneca is cutting a further 7,300 jobs and expects earnings to fall this year as patents on key drugs expire and governments in Europe and the United States squeeze prices.
Britain's second-biggest drugmaker said the latest phase of cost cutting would deliver a further $1.6bn (£1bn) in annual benefits by the end of 2014.
Core earnings this year, which exclude some items, are forecast by the company to be between $6.00 and $6.30 a share, down from $7.28 in 2011.
